Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Lyka Labs Limited ( (IN:LYKALABS) ) is now available.
Lyka Labs Limited has secured final approval for the amalgamation of group entity Lyka Exports Limited, after the National Company Law Tribunal in Ahmedabad sanctioned the merger and the order was filed with the Registrar of Companies. The scheme, effective from April 8, 2026 with an appointed date of April 1, 2022, consolidates the businesses and results in an automatic increase in Lyka Labs’ authorised share capital to Rs. 59 crore, enhancing its financial flexibility and corporate structure.
The company’s authorised capital now comprises 5.7 crore equity shares of Rs. 10 each and 2 lakh redeemable preference shares of Rs. 100 each, reflecting the combined capital base of the transferor and transferee entities. This restructuring is expected to streamline group operations, simplify the shareholding framework, and potentially strengthen Lyka Labs’ balance sheet and positioning in the pharmaceutical market.
More about Lyka Labs Limited
Lyka Labs Limited operates in the pharmaceutical sector, with activities that include manufacturing and marketing of medicinal formulations. The company serves domestic and international markets through branded and generic products, and is listed on both the BSE and the National Stock Exchange of India.
Average Trading Volume: 5,752
Technical Sentiment Signal: Sell
Current Market Cap: 2.09B INR
Learn more about LYKALABS stock on TipRanks’ Stock Analysis page.